Seven Editora
##common.pageHeaderLogo.altText##
##common.pageHeaderLogo.altText##


Contato

  • Seven Publicações Ltda CNPJ: 43.789.355/0001-14 Rua: Travessa Aristides Moleta, 290- São José dos Pinhais/PR CEP: 83045-090
  • Contato Principal
  • Nathan Albano Valente
  • (41) 9 8836-2677
  • editora@sevenevents.com.br
  • Contato para Suporte Técnico
  • contato@sevenevents.com.br

Remdesivir: a strategy to confront the COVID-19 virus

Bessa G;
Alcântara de Castro M;
Barbosa Ferreira dos Santos R;
de Sousa Pinto M;
Vieira de Moraes Filho A

Grasiela Bessa

Michele Alcântara de Castro

Ramila Barbosa Ferreira dos Santos

Murillo de Sousa Pinto

Aroldo Vieira de Moraes Filho


Resumo

December 2019, a new type of coronavirus was found to have emerged and the World Health Organization declared a state of public health emergency. In view of this Remdesivir was pointed out in many countries as a possible candidate for the treatment of Sars-Cov-2. Given these assumptions, this paper aims to highlight the current evidence on the mechanism of action of this drug in cells infected with COVID-19 through a literature review. Remdesivir is defined as a nucleoside analog prodrug substituted with 10-cyano. Its main function is to inhibit viral replication by competing with endogenous nucleotides for viral RNA incorporation. In a randomized double-blind study, intravenous Remdesivir had no efficacy on time to clinical improvement, mortality, or time to viral clearance in patients with severe COVID-19. In another study patients who received Remdesivir had a 10-day faster recovery compared to those who received placebo. It is concluded that one study was able to satisfactorily demonstrate the use of Remdesivir in patients with COVID-19, as patients had a short recovery time compared to placebo. However, more studies are needed to prove the efficacy of the drug in combating coronavirus.

 

DOI: 10.56238/pacfdnsv1-002


Creative Commons License

Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2023 Grasiela Bessa, Michele Alcântara de Castro, Ramila Barbosa Ferreira dos Santos, Murillo de Sousa Pinto, Aroldo Vieira de Moraes Filho

##plugins.themes.gdThemes.article.Authors##

  • Grasiela Bessa
  • Michele Alcântara de Castro
  • Ramila Barbosa Ferreira dos Santos
  • Murillo de Sousa Pinto
  • Aroldo Vieira de Moraes Filho